Evidence map›Paper›PMID 29035090›Full record

Observational studyAnnals of the American Thoracic Society2018

Early Respiratory Bacterial Detection and Antistaphylococcal Antibiotic Prophylaxis in Young Children with Cystic Fibrosis.

Matthew N Hurley, Andrew Fogarty, Tricia M McKeever, Christopher H Goss, Margaret Rosenfeld, Alan R Smyth

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in Annals of the American Thoracic Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Polyclonality, Shared Strains, and Convergent Evolution in Chronic Cystic FibrosisAmerican journal of respiratory and critical care medicine · 2021
    Article
  4. Professor Pangloss and the Pangenome: DoesAmerican journal of respiratory and critical care medicine · 2021
    Article
  5. Article
  6. Shifting Landscape of Airway Infection in Early Cystic Fibrosis.American journal of respiratory and critical care medicine · 2019
    Article
  7. Review
  8. Article
  9. Update in Cystic Fibrosis 2018.American journal of respiratory and critical care medicine · 2019
    Review
  10. Antimicrobial Treatment ofFrontiers in pharmacology · 2019
    Review
  11. Breathe (Sheffield, England) · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Matthew N Hurley1 Division of Child Health, Obstetrics & Gynaecology, University of Nottingham, and.ORCID 0000-0002-2439-8522
Andrew Fogarty3 Division of Epidemiology and Public Health, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, United Kingdom.
Tricia M McKeever3 Division of Epidemiology and Public Health, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, United Kingdom.ORCID 0000-0003-0914-0416
Christopher H Goss4 Department of Medicine and.
Margaret Rosenfeld6 Seattle Children's Research Institute, Seattle, Washington; and.
Alan R Smyth1 Division of Child Health, Obstetrics & Gynaecology, University of Nottingham, and.ORCID 0000-0001-5494-5438
University of Nottingham · GBNottingham University Hospitals NHS Trust · GBUniversity of Washington · USUniversity of Washington Medical Center · US

Funding

Medical Research Council MR/N005953/1Wellcome TrustWellcome Trust WT092295MA
6 · The paper itself

Abstract

rationaleConsensus is lacking regarding antistaphylococcal antibiotic prophylaxis use for young children with cystic fibrosis. Prophylaxis is recommended in the United Kingdom, but it is recommended against in the United States.

objectivesTo test the hypothesis that antistaphylococcal antibiotic prophylaxis is associated with a decreased risk of Staphylococcus aureus acquisition but no increased risk of Pseudomonas aeruginosa acquisition.

methodsWe undertook a longitudinal observational study of children with cystic fibrosis who were recruited from birth (or from their first registry entry in the period) and followed until the age of 4 years (1,500 d) using 2000-2009 data from the UK Cystic Fibrosis Trust and Cystic Fibrosis Foundation registries. Children were excluded if they had a positive culture result for S. aureus or P. aeruginosa, or if they were receiving inhaled antibiotics, at the first encounter. Time to first S. aureus and P. aeruginosa detection in the UK/U.S. cohorts was compared using a Cox proportional hazards model. A UK-based analysis compared the same for those receiving flucloxacillin with those who received no prophylaxis. We included the following covariates: sex, age at registry entry, dornase alfa use, genotype, and center size.

resultsThe primary analysis comprised 1,074 UK and 3,677 U.S. children. The risk of first detection was greater in U.S. children than in UK children for S. aureus (hazard ratio [HR], 5.79; 95% confidence interval [CI], 4.85, 6.90; P < 0.001) and P. aeruginosa (HR, 1.92; 95% CI, 1.65, 2.24; P < 0.001). In the UK analysis, we compared 278 children receiving flucloxacillin and 306 receiving no prophylaxis. Flucloxacillin was not associated with a reduced risk of S. aureus detection (HR, 1.22; 95% CI, 0.74, 2.0; P = 0.43), but it was associated with an increased risk of P. aeruginosa detection (HR, 2.53; 95% CI, 1.71, 3.74; P < 0.001). None of the covariates significantly affected the risk estimate in either analysis.

conclusionsThe risk of first detection of S. aureus and P. aeruginosa was greater in the United States than in the United Kingdom. In the United Kingdom, the risk of first P. aeruginosa detection was increased among those receiving flucloxacillin compared with those who received no prophylaxis. These observational findings should be examined in randomized controlled trials.

Indexed as

Antibiotic ProphylaxisAnti-Bacterial AgentsChildChild, PreschoolCystic FibrosisEarly DiagnosisFemaleHumansMaleProportional Hazards ModelsPseudomonas aeruginosaPseudomonas InfectionsRegistriesStaphylococcal InfectionsStaphylococcus aureusUnited KingdomAnti-Bacterial Agentsantibioticschildrencystic fibrosisinfectionprophylaxis

Identifiers

PMID29035090
PMCPMC5822417
OpenAlexW2765658974

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.